Purple Biotech Ltd.
PPBT
Price:
$2.97
Market Cap:
$5.72M
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and ...[Read more]
Industry
Biotechnology
IPO Date
2015-11-20
Stock Exchange
NASDAQ
Ticker
PPBT
PE Ratio
[-0.23]
ROE
[-48.16%]
Current Ratio
[1.22]
Dividend Yield
[0%]
Enterprise Value
[-541411.00]
Dividend History
The ROE as of November 2024 (TTM) for Purple Biotech Ltd. (PPBT) is -48.16%
According to Purple Biotech Ltd.’s latest financial reports and current stock price. The company's current ROE is -48.16%. This represents a change of 305.64% compared to the average of -11.87% of the last 4 quarters.
Purple Biotech Ltd. (PPBT) Historical ROE (quarterly & annually)
How has PPBT ROE performed in the past?
The mean historical ROE of Purple Biotech Ltd. over the last ten years is -123.70%. The current -48.16% ROE has changed -61.07% with respect to the historical average. Over the past ten years (40 quarters), PPBT's ROE was at its highest in in the December 2017 quarter at 23.04%. The ROE was at its lowest in in the September 2015 quarter at -958.78%.
Average
-123.70%
Median
-53.77%
Minimum
-679.43%
Maximum
-15.63%
Purple Biotech Ltd. (PPBT) ROE by Quarter and Year
Discovering the peaks and valleys of Purple Biotech Ltd. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 103.27%
Maximum Annual ROE = -15.63%
Minimum Annual Increase = -344.57%
Minimum Annual ROE = -679.43%
| Year | ROE | Change |
|---|---|---|
| 2023 | -58.12% | 30.92% |
| 2022 | -44.39% | 55.87% |
| 2021 | -28.48% | 82.27% |
| 2020 | -15.63% | -73.34% |
| 2019 | -58.61% | 18.61% |
| 2018 | -49.42% | -70.55% |
| 2017 | -167.81% | 85.25% |
| 2016 | -90.59% | 103.27% |
| 2015 | -44.56% | -93.44% |
| 2014 | -679.43% | -344.57% |
Purple Biotech Ltd. (PPBT) Average ROE
How has PPBT ROE performed in the past?
The current ROE of Purple Biotech Ltd. (PPBT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-43.66%
5-year avg
-41.05%
10-year avg
-123.70%
Purple Biotech Ltd. (PPBT) ROE vs. Peers
How is PPBT’s ROE compared to its peers?
Purple Biotech Ltd.’s ROE is greater than Pluri Inc. (-482.73%), greater than BioLineRx Ltd. (-225.62%), greater than Aridis Pharmaceuticals, Inc. (-62.63%), greater than Enlivex Therapeutics Ltd. (-71.76%), greater than Anebulo Pharmaceuticals, Inc. (-138.92%), greater than PMV Pharmaceuticals, Inc. (-21.96%), greater than Miromatrix Medical Inc. (-119.21%), less than ZIVO Bioscience, Inc. (673.84%), greater than Bionomics Limited (-184.73%), greater than Bio-Path Holdings, Inc. (-2842.40%), less than Endonovo Therapeutics, Inc. (15.62%), less than Cingulate Inc. (11.47%), greater than Soleno Therapeutics, Inc. (-43.25%), less than Cingulate Inc. (0%), less than SAB Biotherapeutics, Inc. (11.47%), greater than Cadrenal Therapeutics, Inc. Common Stock (-94.04%), greater than Monopar Therapeutics Inc. (-93.71%), greater than null (-110.60%),
| Company | ROE | Market cap |
|---|---|---|
| -482.73% | $24.94M | |
| -225.62% | $37.41M | |
| -62.63% | $8.91K | |
| -71.76% | $27.83M | |
| -138.92% | $49.01M | |
| -21.96% | $84.49M | |
| -119.21% | $92.95M | |
| 673.84% | $68.83M | |
| -184.73% | $3.41M | |
| -2842.40% | $3.61M | |
| 15.62% | $350.63K | |
| 11.47% | $11.66M | |
| -43.25% | $2.18B | |
| 0% | $11.86M | |
| 11.47% | $37.29M | |
| -94.04% | $15.24M | |
| -93.71% | $87.22M | |
| -110.60% | $0 |
Build a custom stock screener for Purple Biotech Ltd. (PPBT) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Purple Biotech Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Purple Biotech Ltd. (PPBT) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Purple Biotech Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Purple Biotech Ltd.'s ROE?
How is the ROE calculated for Purple Biotech Ltd. (PPBT)?
What is the highest ROE for Purple Biotech Ltd. (PPBT)?
What is the 3-year average ROE for Purple Biotech Ltd. (PPBT)?
What is the 5-year average ROE for Purple Biotech Ltd. (PPBT)?
How does the current ROE for Purple Biotech Ltd. (PPBT) compare to its historical average?